Ironwood Pharmaceuticals is trading 5.04% lower at $3.77, with no fresh company-specific catalyst identified. - The investor-relations press-release page lists no announcement dated October 1; its latest release is dated September 3. - The broader backdrop is risk-off, with a sharp rise in Treasury yields and major indexes lower. These moves may be weighing on shares, but available evidence does not establish a direct cause for the decline.